Who Researches This?
Who Researches FOXO4-DRI?
FOXO4-DRI is researched by people at the cutting edge of anti-aging science — specifically the senolytic approach to aging. If you believe cellular senescence is a key driver of aging (the 'hallmarks of aging' framework), FOXO4-DRI represents a targeted molecular approach to clearing senescent cells. It's relevant for longevity researchers, those comparing senolytics (dasatinib+quercetin, fisetin, navitoclax), and anyone studying the biology of cellular senescence. Note: this is a preclinical compound with no human safety data.
Related Resources
- Comparisons: Epitalon vs FOXO4-DRI
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
What Is FOXO4-DRI?
FOXO4-DRI was developed by Peter de Keizer and colleagues at Erasmus University Medical Center (Rotterdam). Published in Cell in 2017, the research demonstrated that a modified peptide could selectively kill senescent cells in aged mice, restoring aspects of youthful function.
The 'DRI' stands for D-Retro-Inverso — a peptide engineering technique that uses D-amino acids (mirror images of natural L-amino acids) in reverse sequence. This produces a peptide with similar 3D surface topology to the natural L-peptide but with dramatically improved protease resistance, since mammalian enzymes cannot efficiently degrade D-amino acid peptides.
Mechanism of Action
In normal cells, p53 is a tumor suppressor that triggers apoptosis when cells become damaged or dysfunctional. In senescent cells, FOXO4 binds and sequesters p53 in the nucleus, preventing it from activating apoptosis pathways — keeping the damaged cell alive.
FOXO4-DRI works by:
- Competitive inhibition: FOXO4-DRI competes with endogenous FOXO4 for p53 binding
- p53 release: Displaces p53 from FOXO4 sequestration in senescent cell nuclei
- Selective apoptosis: Released p53 translocates to mitochondria and triggers intrinsic apoptosis — but only in senescent cells where FOXO4-p53 interaction is active
- Healthy cell sparing: Non-senescent cells do not rely on FOXO4-p53 interaction for survival, so FOXO4-DRI has minimal effect
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
No spam · Unsubscribe anytime
Dosage Overview
Mouse dosing in the original 2017 publication: 5 mg/kg intraperitoneal injection, administered three times per week for several weeks. No human dosing has been established. As a D-retro-inverso peptide, FOXO4-DRI has much longer stability than conventional peptides.
Human-equivalent dosing has not been validated. Some research community members have attempted self-experimentation, but no formal pharmacokinetic or safety studies exist in humans.
Side Effects & Safety
- No human safety data: FOXO4-DRI is preclinical only
- Mouse studies: No significant toxicity reported; mice showed improved rather than impaired health markers
- Theoretical concerns: Senescent cells play beneficial roles in wound healing and tumor suppression — excessive clearance could impair these processes
- p53 activation: While selective for senescent cells, any compound that activates p53 warrants careful safety evaluation
- Cost and availability: FOXO4-DRI is expensive to synthesize as a D-amino acid peptide, limiting access